<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123614</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 75978</org_study_id>
    <nct_id>NCT03123614</nct_id>
  </id_info>
  <brief_title>Loteprednol vs. Prednisolone and Fluorometholone</brief_title>
  <official_title>Efficacy and Safety of Loteprednol 0.5% Gel for Routine Prophylaxis After Photorefractive Keratectomy Compared to Prednisolone Acetate 1% Suspension and Fluorometholone 0.1% Suspension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corneal haze, in which the cornea becomes cloudy, is a well-known and a potentially&#xD;
      vision-threatening postoperative complication of photorefractive keratectomy (PRK). Topical&#xD;
      ophthalmic corticosteroids are routinely prescribed by most surgeons postoperatively to help&#xD;
      prevent this complication.&#xD;
&#xD;
      Goals of topical steroids use after PRK include effective modulation of the healing response&#xD;
      to prevent corneal haze while at the same time minimizing side effects, such as intraocular&#xD;
      pressure elevation or cataract formation. Loteprednol etabonate is a corticosteroid that&#xD;
      exerts its therapeutic effects and is then quickly changed into inactive metabolites. This&#xD;
      relatively fast metabolism of loteprednol gives it a lower side effect profile than other&#xD;
      steroids, including a smaller effect on intraocular pressure. In the ophthalmic literature,&#xD;
      there is currently no consensus on a standard regimen or which type of corticosteroid should&#xD;
      be used after PRK.&#xD;
&#xD;
      Investigators are conducting a prospective, randomized trial to compare the incidence of&#xD;
      intraocular pressure rise and visually significant postoperative corneal haze after PRK with&#xD;
      the use of loteprednol 0.5% gel compared to the use of earlier generation steroids,&#xD;
      prednisolone acetate 1% suspension and fluorometholone 0.1% suspension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2014</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Examiners are masked to the treatment arm when obtaining measurements of intraocular pressure (IOP) and grading corneal haze.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intraocular Pressure (IOP) From Baseline Through Month 3</measure>
    <time_frame>Baseline, 1 week post-op, 1 month post-op, 2 months post-op, 3 months post-op</time_frame>
    <description>Intraocular pressure will be measured by applanation tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With Corneal Haze</measure>
    <time_frame>12 months</time_frame>
    <description>As determined by slit lamp examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Best uncorrected visual acuity will be measured at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Best uncorrected visual acuity will be measured at 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Intraocular Pressure</condition>
  <condition>Corneal Opacity</condition>
  <arm_group>
    <arm_group_label>Loteprednol Etabonate 0.5% Oph Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone acetate 1% Oph Susp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate 0.5% Oph Gel</intervention_name>
    <arm_group_label>Loteprednol Etabonate 0.5% Oph Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 1% Oph Susp</intervention_name>
    <arm_group_label>Prednisolone acetate 1% Oph Susp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects who are deemed suitable candidates for PRK after routine refractive&#xD;
             surgery screening will be considered eligible for participation in this study.&#xD;
&#xD;
          -  Subjects must be at least 21 years of age and not pregnant or nursing (due to&#xD;
             fluctuations in visual parameters during pregnancy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Selection will be consistent with the current standard of care for PRK. Any patient&#xD;
             that is not a suitable candidate for PRK will not be included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Mifflin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah Moran Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moran Eye Center - Midvalley Location</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <results_first_submitted>August 23, 2020</results_first_submitted>
  <results_first_submitted_qc>November 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2020</results_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Mark Mifflin</investigator_full_name>
    <investigator_title>Professor, Ophthalmology/Visual Sciences</investigator_title>
  </responsible_party>
  <keyword>Photorefractive keratectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Opacity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03123614/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Loteprednol Etabonate 0.5% Oph Gel</title>
          <description>Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.&#xD;
Loteprednol Etabonate 0.5% Oph Gel</description>
        </group>
        <group group_id="P2">
          <title>Prednisolone Acetate 1% Oph Susp</title>
          <description>Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.&#xD;
Prednisolone Acetate 1% Oph Susp</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loteprednol Etabonate 0.5% Oph Gel</title>
          <description>Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.&#xD;
Loteprednol Etabonate 0.5% Oph Gel</description>
        </group>
        <group group_id="B2">
          <title>Prednisolone Acetate 1% Oph Susp</title>
          <description>Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.&#xD;
Prednisolone Acetate 1% Oph Susp</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="131"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" spread="8.8"/>
                    <measurement group_id="B2" value="35.3" spread="6.2"/>
                    <measurement group_id="B3" value="35.0" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.38" spread="2.11"/>
                    <measurement group_id="B2" value="14.30" spread="2.13"/>
                    <measurement group_id="B3" value="14.34" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Intraocular Pressure (IOP) From Baseline Through Month 3</title>
        <description>Intraocular pressure will be measured by applanation tonometry</description>
        <time_frame>Baseline, 1 week post-op, 1 month post-op, 2 months post-op, 3 months post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate 0.5% Oph Gel</title>
            <description>Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.&#xD;
Loteprednol Etabonate 0.5% Oph Gel</description>
          </group>
          <group group_id="O2">
            <title>Prednisolone Acetate 1% Oph Susp</title>
            <description>Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.&#xD;
Prednisolone Acetate 1% Oph Susp</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intraocular Pressure (IOP) From Baseline Through Month 3</title>
          <description>Intraocular pressure will be measured by applanation tonometry</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline intraocular pressure (IOP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.38" spread="2.11"/>
                    <measurement group_id="O2" value="14.30" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP 1 week postop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.67" spread="2.34"/>
                    <measurement group_id="O2" value="13.28" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP 1 month postop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.15" spread="2.88"/>
                    <measurement group_id="O2" value="14.60" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP 2 months postop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.36" spread="2.53"/>
                    <measurement group_id="O2" value="13.16" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP 3 months postop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.15" spread="2.43"/>
                    <measurement group_id="O2" value="12.22" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With Corneal Haze</title>
        <description>As determined by slit lamp examination</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate 0.5% Oph Gel</title>
            <description>Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.&#xD;
Loteprednol Etabonate 0.5% Oph Gel</description>
          </group>
          <group group_id="O2">
            <title>Prednisolone Acetate 1% Oph Susp</title>
            <description>Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.&#xD;
Prednisolone Acetate 1% Oph Susp</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Corneal Haze</title>
          <description>As determined by slit lamp examination</description>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uncorrected Visual Acuity</title>
        <description>Best uncorrected visual acuity will be measured at 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate 0.5% Oph Gel</title>
            <description>Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.&#xD;
Loteprednol Etabonate 0.5% Oph Gel</description>
          </group>
          <group group_id="O2">
            <title>Prednisolone Acetate 1% Oph Susp</title>
            <description>Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.&#xD;
Prednisolone Acetate 1% Oph Susp</description>
          </group>
        </group_list>
        <measure>
          <title>Uncorrected Visual Acuity</title>
          <description>Best uncorrected visual acuity will be measured at 3 months</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.078" spread="0.10"/>
                    <measurement group_id="O2" value="-0.075" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity at 3 Months</title>
        <description>Best uncorrected visual acuity will be measured at 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate 0.5% Oph Gel</title>
            <description>Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.&#xD;
Loteprednol Etabonate 0.5% Oph Gel</description>
          </group>
          <group group_id="O2">
            <title>Prednisolone Acetate 1% Oph Susp</title>
            <description>Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.&#xD;
Prednisolone Acetate 1% Oph Susp</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity at 3 Months</title>
          <description>Best uncorrected visual acuity will be measured at 3 months</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.120" spread="0.059"/>
                    <measurement group_id="O2" value="-0.114" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years and 10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Loteprednol Etabonate 0.5% Oph Gel</title>
          <description>Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.&#xD;
Loteprednol Etabonate 0.5% Oph Gel</description>
        </group>
        <group group_id="E2">
          <title>Prednisolone Acetate 1% Oph Susp</title>
          <description>Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.&#xD;
Prednisolone Acetate 1% Oph Susp</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Non-visually significant corneal haze</sub_title>
                <description>Cornea haze</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Mifflin, MD</name_or_title>
      <organization>University of Utah Moran Eye Center</organization>
      <phone>801-213-4152</phone>
      <email>Mark.Mifflin@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

